Full-Time

Associate Director

HCP Marketing, Alzheimer's Disease Agitation

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Compensation Overview

$160k - $190kAnnually

+ Annual Bonus + Equity

Senior, Expert

New York, NY, USA

On-site requirement of at least three days per week.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Branding/Brand Strategy
Requirements
  • BA or BS, advanced degree preferred
  • 8-10 years of experience in the pharmaceutical industry including a minimum of 6 years in marketing
  • HCP Marketing experience
  • Launch experience strongly preferred
  • Strong personal drive, highly collaborative, problem solver that exhibits strategic insight and innovative agility
  • Ability to meet multiple deadlines across a variety of projects with a high degree of accuracy and efficiency
  • Demonstrated ability to achieve results in a highly matrixed organization
  • Ability to work on site Monday, Tuesday & Thursday. We are unable to consider candidates looking for fully remote roles.
Responsibilities
  • Lead development and execution of HCP material content ensuring KOL input into the development of all material
  • Work cross-functionally to develop a comprehensive peer-to-peer strategy for AXS-05
  • Build a diverse, experienced speakers bureau for AXS-05 including identification, contracting and training of KOLs
  • Partner with Training and Marketing Operations to develop and execute a comprehensive training program
  • Lead Legal / Regulatory / Medical review of HCP materials
  • Lead all advisory board meetings for AXS-05 in preparation for launch and develop a structured format to gain continuous insight from KOLs post-launch
  • Identify strategic market opportunities and make recommendations to enhance brand strategy
  • Manage timelines and budgets in accordance with brand plan
Desired Qualifications
  • Demonstrated proactive, creative and entrepreneurial approach
  • CNS disease experience
  • Strong project and process management skills, including competency in agency management and budget management
  • Strong marketing aptitude
  • Strong interpersonal and presentation skills
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased investment in CNS treatments boosts Axsome's pipeline potential.
  • FDA's fast-tracking emphasis could expedite Axsome's drug approvals, especially AXS-05.
  • Personalized medicine trends offer Axsome opportunities for tailored, effective therapies.

What critics are saying

  • Increased competition in CNS treatments may impact Axsome's market share.
  • Potential delays in AXS-07 approval could affect launch timeline and revenue.
  • Reliance on key products like AXS-05 makes Axsome vulnerable to setbacks.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders, addressing unmet medical needs with innovative therapies.
  • AXS-05, a flagship product, has FDA Breakthrough Therapy Designation for depression.
  • Axsome's balanced portfolio includes both clinical and research stage products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Insider Monkey
Feb 23rd, 2025
Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025

Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma stock So Far in 2025.

Investing.com
Dec 19th, 2024
Amgen stock touches 52-week low at $257.77 amid market shifts

The firm sees potential in Sarepta's Elevidys for Duchenne muscular dystrophy, Legend's ability to double its manufacturing capacity, and Axsome's anticipated launch of AXS-07 for migraines.

MarketBeat
Dec 13th, 2024
Captrust Financial Advisors Invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Captrust Financial Advisors invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 4th, 2024
Erste Asset Management GmbH Invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Erste Asset Management GmbH invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 2nd, 2024
PDT Partners LLC Makes New $1.05 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

PDT Partners LLC makes new $1.05 million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).